Destiny Pharma to join panel discussion at LSX

RNS Number : 6222N
Destiny Pharma PLC
02 February 2021
 

Destiny Pharma PLC

("Destiny" or "the Company")

 

 

Destiny Pharma to Participate in Panel Discussion at the

7th Annual LSX World Congress 2021

 

 

Brighton, UK, 2 February 2021  - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that Neil Clark, Chief Executive Officer, will be taking part in a panel discussion at the 7th Annual LSX World Congress to be held virtually between 1-5 February, 2021.

 

The panel discussion 'Investing In Infectious Disease - How Will The Covid Pandemic Transform The Development, Commercialisation, And Partnering Landscape?' will be held at 15:00 GMT on 2nd February 2021.

 

The panel will be made available through the conference website and will be available to registered participants throughout the event -  www.lsxleaders.com/lsx-world-congress .

 

Ends -

 

Enquiries:

 

Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark (Chief Executive Officer)

Shaun Claydon (Chief Financial Officer and Company Secretary)

 

finnCap Limited - Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)

Alice Lane (ECM)

 

WG Partners LLP - Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig

 

Optimum Strategic Communication

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

 

For further information, please visit https://www.destinypharma.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFERFAILIIL
UK 100

Latest directors dealings